首页 > 最新文献

Parkinsonism & related disorders最新文献

英文 中文
TOR1AIP2 as a candidate gene for dystonia-hemichorea/hemiballism
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-11 DOI: 10.1016/j.parkreldis.2025.107781
Efthymia Kafantari , Victoria J. Hernandez , Ján Necpál , Marina Leonidou , Regina Baureder , Carola Hedberg-Oldfors , Robert Jech , Michael Zech , Thomas U. Schwartz , Andreas Puschmann
Dystonia is a movement disorder characterized by genetic and clinical heterogeneity. A recurring p.(Glu303del)-deletion in TOR1A is a well-established cause for DYT-TOR1A (DYT1), an autosomal dominant early-onset isolated dystonia. TOR1A encodes TorsinA, an AAA + ATPase located in the nuclear envelope. By whole exome analyses of a family with a novel dystonia-hemichorea-/hemiballism phenotype, we identified a TOR1AIP2 NM_001199260.2 c.1234A > G p.(Arg412Gly) variant. The variant is very rare in databases and was absent from whole exome data from >1000 dystonia patients. TOR1AIP2 encodes LULL1, a transmembrane protein that activates TorsinA, and correct interaction between TorsinA and LULL1 is essential for proper nuclear envelope architecture. The p.(Arg412Gly) variant disrupts the binding interface between TorsinA and LULL1 around p.Arg412; this same interface is also impaired in DYT1. Functional analyses via a co-purification assay revealed that interaction between TorsinA-LULL1Arg412Gly is weaker than the wild-type interaction, and that it resembles the situation in DYT1 (TorsinAΔE303-LULL1). A second family with milder dystonia, hemichorea, and stereotypic leg flexion during gait and a TOR1AIP2 p.(Gln338His) variant was identified. The clinical phenotype of both families shared proximal arm movements, and flutter in facial musculature. Expressivity of the movement disorder symptoms was variable. Several proteins in the nuclear envelope have been implicated in various forms of neurodevelopmental disorders with dystonia. Taken together, our findings suggest TOR1AIP2 as a new candidate gene implicated in a complex hereditary movement disorder with dystonia and hemichorea/hemiballism.
{"title":"TOR1AIP2 as a candidate gene for dystonia-hemichorea/hemiballism","authors":"Efthymia Kafantari ,&nbsp;Victoria J. Hernandez ,&nbsp;Ján Necpál ,&nbsp;Marina Leonidou ,&nbsp;Regina Baureder ,&nbsp;Carola Hedberg-Oldfors ,&nbsp;Robert Jech ,&nbsp;Michael Zech ,&nbsp;Thomas U. Schwartz ,&nbsp;Andreas Puschmann","doi":"10.1016/j.parkreldis.2025.107781","DOIUrl":"10.1016/j.parkreldis.2025.107781","url":null,"abstract":"<div><div>Dystonia is a movement disorder characterized by genetic and clinical heterogeneity. A recurring p.(Glu303del)-deletion in <em>TOR1A</em> is a well-established cause for DYT-<em>TOR1A</em> (DYT1), an autosomal dominant early-onset isolated dystonia. <em>TOR1A</em> encodes TorsinA, an AAA + ATPase located in the nuclear envelope. By whole exome analyses of a family with a novel dystonia-hemichorea-/hemiballism phenotype, we identified a <em>TOR1AIP2</em> NM_001199260.2 c.1234A &gt; G p.(Arg412Gly) variant. The variant is very rare in databases and was absent from whole exome data from &gt;1000 dystonia patients. <em>TOR1AIP2</em> encodes LULL1, a transmembrane protein that activates TorsinA, and correct interaction between TorsinA and LULL1 is essential for proper nuclear envelope architecture. The p.(Arg412Gly) variant disrupts the binding interface between TorsinA and LULL1 around p.Arg412; this same interface is also impaired in DYT1. Functional analyses via a co-purification assay revealed that interaction between TorsinA-LULL1<sup>Arg412Gly</sup> is weaker than the wild-type interaction, and that it resembles the situation in DYT1 (TorsinA<sup>ΔE303</sup>-LULL1). A second family with milder dystonia, hemichorea, and stereotypic leg flexion during gait and a <em>TOR1AIP2</em> p.(Gln338His) variant was identified. The clinical phenotype of both families shared proximal arm movements, and flutter in facial musculature. Expressivity of the movement disorder symptoms was variable. Several proteins in the nuclear envelope have been implicated in various forms of neurodevelopmental disorders with dystonia. Taken together, our findings suggest <em>TOR1AIP2</em> as a new candidate gene implicated in a complex hereditary movement disorder with dystonia and hemichorea/hemiballism.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107781"},"PeriodicalIF":3.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of bright light therapy on Parkinson's disease: A pilot study using vestibular-evoked myogenic potentials 强光疗法对帕金森病的影响:使用前庭诱发肌源性电位的试点研究
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.parkreldis.2025.107776
Wei-ye Xie , Wen-xiang Duan , Ying Chen , Meng-xing Tao , Han-xing Li , Fan Gao , Jie-yun Yin , Jia-hui Yan , Fen Wang , Cheng-jie Mao , Yun Shen , Chun-feng Liu

Introduction

Bright light therapy (BLT) has been proved to have beneficial effects on Parkinson's disease (PD). Brainstem pathways improvements might be crucial to BLT, but the mechanisms remained unclear. The aim of this study is to validate whether BLT improves clinical symptoms in PD and thus explore the possible mechanisms of brainstem pathways evaluated by vestibular-evoked myogenic potentials (VEMPs).

Methods

A total of 22 PD patients participated were enrolled in this crossover randomized placebo-controlled study. Participants received either one month of BLT or dim light therapy (DLT), separated by a 1-month wash-out period, and underwent clinical scales and VEMPs evaluations before and after each intervention. Mixed-effects regression models were used to determine the effect between BLT and DLT on PD patients by the differentials of clinical scales (Δscales) and VEMPs (ΔVEMPs). Correlations between the improvement of clinical symptoms and VEMPs parameters improvements were analyzed in PD patients receiving BLT.

Results

Excessive daytime sleepiness, anxiety, life quality and autonomic function were improved after BLT. Compared to DLT, the difference was not significant. There were significant differences of cervical VEMPs (cVEMP) and ocular VEMPs (oVEMP) peak latencies after BLT. Compared with DLT, there was significant difference in ΔLp13, ΔRp13 and ΔLp11 peak latencies after BLT.

Conclusions

BLT may be a valuable non-pharmacological intervention for improving brainstem function, thereby enhancing quality of life and overall health in PD patients.
导言亮光疗法(BLT)已被证明对帕金森病(PD)有益处。脑干通路的改善可能是亮光疗法的关键,但其机制仍不清楚。本研究旨在验证 BLT 是否能改善帕金森病的临床症状,从而探索通过前庭诱发肌源性电位(VEMPs)评估脑干通路的可能机制。参加者接受了为期一个月的BLT或暗光疗法(DLT),中间有一个月的冲淡期,并在每次干预前后接受了临床量表和VEMPs评估。混合效应回归模型通过临床量表(Δscales)和VEMPs(ΔVEMPs)的差异来确定BLT和DLT对PD患者的影响。结果 接受BLT治疗后,白天过度嗜睡、焦虑、生活质量和自主神经功能均得到改善。与DLT相比,差异不显著。BLT后,颈部VEMPs(cVEMP)和眼部VEMPs(oVEMP)峰值潜伏期有明显差异。与DLT相比,BLT后ΔLp13、ΔRp13和ΔLp11峰值潜伏期有显著差异。
{"title":"The impact of bright light therapy on Parkinson's disease: A pilot study using vestibular-evoked myogenic potentials","authors":"Wei-ye Xie ,&nbsp;Wen-xiang Duan ,&nbsp;Ying Chen ,&nbsp;Meng-xing Tao ,&nbsp;Han-xing Li ,&nbsp;Fan Gao ,&nbsp;Jie-yun Yin ,&nbsp;Jia-hui Yan ,&nbsp;Fen Wang ,&nbsp;Cheng-jie Mao ,&nbsp;Yun Shen ,&nbsp;Chun-feng Liu","doi":"10.1016/j.parkreldis.2025.107776","DOIUrl":"10.1016/j.parkreldis.2025.107776","url":null,"abstract":"<div><h3>Introduction</h3><div>Bright light therapy (BLT) has been proved to have beneficial effects on Parkinson's disease (PD). Brainstem pathways improvements might be crucial to BLT, but the mechanisms remained unclear. The aim of this study is to validate whether BLT improves clinical symptoms in PD and thus explore the possible mechanisms of brainstem pathways evaluated by vestibular-evoked myogenic potentials (VEMPs).</div></div><div><h3>Methods</h3><div>A total of 22 PD patients participated were enrolled in this crossover randomized placebo-controlled study. Participants received either one month of BLT or dim light therapy (DLT), separated by a 1-month wash-out period, and underwent clinical scales and VEMPs evaluations before and after each intervention. Mixed-effects regression models were used to determine the effect between BLT and DLT on PD patients by the differentials of clinical scales (Δscales) and VEMPs (ΔVEMPs). Correlations between the improvement of clinical symptoms and VEMPs parameters improvements were analyzed in PD patients receiving BLT.</div></div><div><h3>Results</h3><div>Excessive daytime sleepiness, anxiety, life quality and autonomic function were improved after BLT. Compared to DLT, the difference was not significant. There were significant differences of cervical VEMPs (cVEMP) and ocular VEMPs (oVEMP) peak latencies after BLT. Compared with DLT, there was significant difference in ΔLp13, ΔRp13 and ΔLp11 peak latencies after BLT.</div></div><div><h3>Conclusions</h3><div>BLT may be a valuable non-pharmacological intervention for improving brainstem function, thereby enhancing quality of life and overall health in PD patients.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107776"},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of an adapted physical activity program in Parkinson's disease: A randomized controlled study (APA-Park)
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.parkreldis.2025.107777
Carole Zanchet , Céline Lambert , Thibaut Boyer , Bruno Pereira , Philippe Derost , Bérengère Debilly , Martine Duclos , Nathalie Boisseau , Ana Marques

Context

Previous studies assessing adapted physical activity (APA) in Parkinson's disease (PD) have been very heterogeneous regarding methodology and intervention, and have generally not addressed the question of combining various types of physical activity with a long-term evaluation.

Objectives

To evaluate the immediate and long-term effect of a 3-month APA program, combining endurance, resistance training and stretching on motor symptoms, body composition, cardiorespiratory function and metabolic profile in PD patients.

Methods

In this controlled trial, we randomly assigned forty-four PD patients in a 1:1 ratio to receive a 3-month APA program (APA + group, n = 22), or freely practice physical activity (APA− group, n = 22). The patients were evaluated for parkinsonian symptoms (UPDRS-III), body composition, cardiorespiratory function and metabolic profile at baseline, immediately after the end of the program (M3) and six months later (M9).

Results

Between baseline and M3, the mean UPDRS-III score decreased in PD patients from the APA + group whereas it increased in the APA− group (−1.2 ± 6.6 vs. +1.9 ± 8.9; p = 0.04), regardless of age, sex, disease duration, dopaminergic treatment, UPDRS-III and axial score at baseline, but these between group differences waned at M9. No between group difference was observed regarding the evolution of body composition, metabolic profile or cardiorespiratory function between baseline, M3 and M9.

Conclusion

A 3-month APA program combining endurance and resistance training plus stretching is more efficient for improving motor symptoms in PD compared to an unstructured engagement in non-specific physical activities. However, the benefits fade away six months after discontinuation of the program.

Statistical analysis conducted by

LAMBERT Céline, CHU Clermont-Ferrand, DRCI, Biostatistics Unit, Clermont-Ferrand, FRANCE.

Registration number

clinicaltrials.gov number NCT02816619.
{"title":"Effect of an adapted physical activity program in Parkinson's disease: A randomized controlled study (APA-Park)","authors":"Carole Zanchet ,&nbsp;Céline Lambert ,&nbsp;Thibaut Boyer ,&nbsp;Bruno Pereira ,&nbsp;Philippe Derost ,&nbsp;Bérengère Debilly ,&nbsp;Martine Duclos ,&nbsp;Nathalie Boisseau ,&nbsp;Ana Marques","doi":"10.1016/j.parkreldis.2025.107777","DOIUrl":"10.1016/j.parkreldis.2025.107777","url":null,"abstract":"<div><h3>Context</h3><div>Previous studies assessing adapted physical activity (APA) in Parkinson's disease (PD) have been very heterogeneous regarding methodology and intervention, and have generally not addressed the question of combining various types of physical activity with a long-term evaluation.</div></div><div><h3>Objectives</h3><div>To evaluate the immediate and long-term effect of a 3-month APA program, combining endurance, resistance training and stretching on motor symptoms, body composition, cardiorespiratory function and metabolic profile in PD patients.</div></div><div><h3>Methods</h3><div>In this controlled trial, we randomly assigned forty-four PD patients in a 1:1 ratio to receive a 3-month APA program (APA + group, n = 22), or freely practice physical activity (APA− group, n = 22). The patients were evaluated for parkinsonian symptoms (UPDRS-III), body composition, cardiorespiratory function and metabolic profile at baseline, immediately after the end of the program (M3) and six months later (M9).</div></div><div><h3>Results</h3><div>Between baseline and M3, the mean UPDRS-III score decreased in PD patients from the APA + group whereas it increased in the APA− group (−1.2 ± 6.6 vs. +1.9 ± 8.9; p = 0.04), regardless of age, sex, disease duration, dopaminergic treatment, UPDRS-III and axial score at baseline, but these between group differences waned at M9. No between group difference was observed regarding the evolution of body composition, metabolic profile or cardiorespiratory function between baseline, M3 and M9.</div></div><div><h3>Conclusion</h3><div>A 3-month APA program combining endurance and resistance training plus stretching is more efficient for improving motor symptoms in PD compared to an unstructured engagement in non-specific physical activities. However, the benefits fade away six months after discontinuation of the program.</div></div><div><h3>Statistical analysis conducted by</h3><div>LAMBERT Céline, CHU Clermont-Ferrand, DRCI, Biostatistics Unit, Clermont-Ferrand, FRANCE.</div></div><div><h3>Registration number</h3><div>clinicaltrials.gov number NCT02816619.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107777"},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021 1990 至 2021 年 204 个国家和地区的早发性帕金森病、地区和国家负担及其可归因风险因素:2021 年全球疾病负担研究的结果
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.parkreldis.2025.107778
Jiayue Wang , Nan Cheng , Zhen Yao , Jinghan Liu , Xiaoru Kan , Zhenliang Hui , Jun Chen

Background

Early-Onset Parkinson's Disease (EOPD), defined as diagnosis before age 40, accounts for 5–10 % of Parkinson's cases and is characterized by slower progression and severe motor and non-motor complications. Its global burden has risen significantly, particularly among younger populations, but comprehensive analyses of trends, disparities, and determinants remain scarce.

Methods

EOPD burden was examined in 204 countries from 1990 to 2021 using Global Burden of Disease (GBD) 2021 data. Age-standardized rates (ASR) for incidence, mortality, and disability-adjusted life years (DALYs) were computed. Estimated annual percentage change (EAPC) was used to analyze temporal trends. Associations with the Socio-Demographic Index (SDI) were investigated, and projections were made for future trends up to 2035 using time-series models.

Results

Global ASRs for incidence, mortality, and DALYs in 2021 were 0.333, 0.006, and 0.461 per 100,000 population, respectively. Incidence and DALYs increased from 1990 to 2021, while mortality fluctuated. Higher burdens were reported in high-SDI regions due to improved detection and longer survival, whereas low-SDI regions faced underdiagnosis and limited healthcare access. Projections suggest a continued rise in EOPD burden, particularly in the 35–39 age group, by 2035.

Conclusion

The increasing worldwide burden of EOPD, along with significant regional and socioeconomic inequalities, underscores the pressing necessity for prompt diagnosis, equitable healthcare access, and specific interventions to address this escalating public health issue.
{"title":"Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021","authors":"Jiayue Wang ,&nbsp;Nan Cheng ,&nbsp;Zhen Yao ,&nbsp;Jinghan Liu ,&nbsp;Xiaoru Kan ,&nbsp;Zhenliang Hui ,&nbsp;Jun Chen","doi":"10.1016/j.parkreldis.2025.107778","DOIUrl":"10.1016/j.parkreldis.2025.107778","url":null,"abstract":"<div><h3>Background</h3><div>Early-Onset Parkinson's Disease (EOPD), defined as diagnosis before age 40, accounts for 5–10 % of Parkinson's cases and is characterized by slower progression and severe motor and non-motor complications. Its global burden has risen significantly, particularly among younger populations, but comprehensive analyses of trends, disparities, and determinants remain scarce.</div></div><div><h3>Methods</h3><div>EOPD burden was examined in 204 countries from 1990 to 2021 using Global Burden of Disease (GBD) 2021 data. Age-standardized rates (ASR) for incidence, mortality, and disability-adjusted life years (DALYs) were computed. Estimated annual percentage change (EAPC) was used to analyze temporal trends. Associations with the Socio-Demographic Index (SDI) were investigated, and projections were made for future trends up to 2035 using time-series models.</div></div><div><h3>Results</h3><div>Global ASRs for incidence, mortality, and DALYs in 2021 were 0.333, 0.006, and 0.461 per 100,000 population, respectively. Incidence and DALYs increased from 1990 to 2021, while mortality fluctuated. Higher burdens were reported in high-SDI regions due to improved detection and longer survival, whereas low-SDI regions faced underdiagnosis and limited healthcare access. Projections suggest a continued rise in EOPD burden, particularly in the 35–39 age group, by 2035.</div></div><div><h3>Conclusion</h3><div>The increasing worldwide burden of EOPD, along with significant regional and socioeconomic inequalities, underscores the pressing necessity for prompt diagnosis, equitable healthcare access, and specific interventions to address this escalating public health issue.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107778"},"PeriodicalIF":3.1,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative corneal nerve beading analysis: A novel biomarker for Parkinson's disease progression
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-04 DOI: 10.1016/j.parkreldis.2025.107764
Sasi Yaisawang , Inturat Attapinan , Ngamjit Kasetsuwan , Usanee Reinprayoon , Krit Pongpirul , Roongroj Bhidayasiri , Jirada Sringean
This study compared corneal nerve beading between Parkinson's disease (PD) patients and healthy controls. Results showed increases in both density and size of nerve beadings in PD, which correlated with disease severity and duration. Corneal nerve beading demonstrated high sensitivity as a potential biomarker for diagnosing and monitoring PD progression.
{"title":"Quantitative corneal nerve beading analysis: A novel biomarker for Parkinson's disease progression","authors":"Sasi Yaisawang ,&nbsp;Inturat Attapinan ,&nbsp;Ngamjit Kasetsuwan ,&nbsp;Usanee Reinprayoon ,&nbsp;Krit Pongpirul ,&nbsp;Roongroj Bhidayasiri ,&nbsp;Jirada Sringean","doi":"10.1016/j.parkreldis.2025.107764","DOIUrl":"10.1016/j.parkreldis.2025.107764","url":null,"abstract":"<div><div>This study compared corneal nerve beading between Parkinson's disease (PD) patients and healthy controls. Results showed increases in both density and size of nerve beadings in PD, which correlated with disease severity and duration. Corneal nerve beading demonstrated high sensitivity as a potential biomarker for diagnosing and monitoring PD progression.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107764"},"PeriodicalIF":3.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking the role of continuous dopaminergic stimulation in Parkinson disease therapy.
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-03-01 DOI: 10.1016/j.parkreldis.2025.107354
Peter A LeWitt

This Viewpoint will examine continuous dopaminergic stimulation (CDS), a concept that has long been invoked as the optimal treatment strategy for improving symptomatic control of Parkinson disease (PD) patients experiencing motor fluctuations. The appeal of CDS has always seemed intuitive and is based, in part, on preclinical investigations implicating pulsatile dopaminergic stimulation as causing motor fluctuations and dyskinesia from levodopa (LD) treatment. However, four large-scale randomized controlled clinical trials testing infused drug delivery have demonstrated only partial effectiveness of CDS at reducing daily OFF time. Other clinical trial data has offered evidence that a reduction in OFF time also can be accomplished from targeting sites in motor pathways downstream from the basal ganglia. Neural plasticity and a CNS calcium receptor signaling compound, ophthalmate, may also hold answers to the regulation of OFF time. Finally, insights derived from neural computational modeling of PD motor pathway pharmacology and the involved electrophysiological connections may guide future understanding of motor fluctuations in PD and their management.

{"title":"Rethinking the role of continuous dopaminergic stimulation in Parkinson disease therapy.","authors":"Peter A LeWitt","doi":"10.1016/j.parkreldis.2025.107354","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107354","url":null,"abstract":"<p><p>This Viewpoint will examine continuous dopaminergic stimulation (CDS), a concept that has long been invoked as the optimal treatment strategy for improving symptomatic control of Parkinson disease (PD) patients experiencing motor fluctuations. The appeal of CDS has always seemed intuitive and is based, in part, on preclinical investigations implicating pulsatile dopaminergic stimulation as causing motor fluctuations and dyskinesia from levodopa (LD) treatment. However, four large-scale randomized controlled clinical trials testing infused drug delivery have demonstrated only partial effectiveness of CDS at reducing daily OFF time. Other clinical trial data has offered evidence that a reduction in OFF time also can be accomplished from targeting sites in motor pathways downstream from the basal ganglia. Neural plasticity and a CNS calcium receptor signaling compound, ophthalmate, may also hold answers to the regulation of OFF time. Finally, insights derived from neural computational modeling of PD motor pathway pharmacology and the involved electrophysiological connections may guide future understanding of motor fluctuations in PD and their management.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107354"},"PeriodicalIF":3.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant 与 RAB32 S71R 变异相关的帕金森病的 18F-FDG PET 研究结果。
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-28 DOI: 10.1016/j.parkreldis.2025.107343
Francesco Cavallieri , Alessandro Fraternali , Annachiara Arnone , Valentina Fioravanti , Edoardo Monfrini , Francesca Di Biasio , Giulia Toschi , Giulia Di Rauso , Giacomo Portaro , Sara Grisanti , Gaetano Salomone , Teresa Kleinz , Paola Mandich , Jefri J. Paul , Christian Beetz , Peter Bauer , Ji Hyun Ko , Matteo Bauckneht , Andrea Melpignano , Angelina Filice , Franco Valzania

Objective

The RAB32 S71R variant has been linked to autosomal dominant Parkinson's disease (RAB32-PD), sharing common biological mechanisms with the leucine-rich repeat kinase-2 (LRRK2) gene. Measurement of regional differences in glucose metabolism with 18F-fluorodeoxyglucose (FDG) PET may improve the understanding of the neural mechanisms of RAB32-related PD and non-mutated PD (NM-PD). In this brief communication, we compared FDG-PET findings of eight RAB32-PD with a cohort of NM-PD.

Methods

Brain FDG-PET study was performed during the ON medication condition under chronic dopaminergic treatment. All images were normalized to a standard FDG-PET template, then a semi‐quantitative analysis was performed on a commercially available fully‐automated post‐processing software (Cortex ID SUITE, GE Healthcare). Clinical assessment included the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Montreal Cognitive Assessment (MoCA). Continuous variables between groups were compared through the Mann-Whitney test while nominal/ordinal variables through the chi-squared test.

Results

Eight RAB32-PD patients (males:3/8; age:65.38 years [±8.73]; disease duration:10.50 years [±5.88]; H&Y:2.81[±1.22]; MDS-UPDRS-III:36.38 [±25.34]; MoCA:24.88[±5.86]) and 19 NM-PD patients (males:11/19; age:60.53 years [±8.00]; disease duration:8.68 years [±5.70]; H&Y:2.39 [±.51]; MDS-UPDRS-III:29.95 [±11.14]; MoCA:24.21 [±6.07]) were included. No statistically significant differences in FDG-PET data and clinical variables were found between RAB32-PD and NM-PD cohorts. In the majority of RAB-32 PD patients a prevalent parietal hypometabolism was observed, similar to previous findings reported in LRRK2-related PD and NM-PD.

Interpretation

This study represents the first description of FDG-PET findings in RAB32-PD patients, highlighting a possible similar pattern of hypometabolism with LRRK2- and NM-PD. Additional studies with matched and comparable control cohorts are needed to confirm these preliminary results.
目的:RAB32 S71R变体与常染色体显性帕金森病(RAB32-PD)有关,与富亮氨酸重复激酶-2(LRRK2)基因具有共同的生物学机制。用 18F- 氟脱氧葡萄糖(FDG)PET 测量葡萄糖代谢的区域性差异可能会加深对 RAB32 相关帕金森病和非变异帕金森病(NM-PD)神经机制的理解。在这篇简短的通讯中,我们比较了 8 例 RAB32-PD 和一组 NM-PD 的 FDG-PET 研究结果:大脑 FDG-PET 研究是在慢性多巴胺能治疗的 ON 药物状态下进行的。所有图像均归一化为标准 FDG-PET 模板,然后使用市售全自动后处理软件(Cortex ID SUITE,GE Healthcare)进行半定量分析。临床评估包括 MDS-统一帕金森病评分量表(MDS-UPDRS)和蒙特利尔认知评估(MoCA)。组间连续变量的比较采用曼-惠特尼检验(Mann-Whitney test),名义/顺序变量的比较采用卡方检验(chi-squared test):8例RAB32-PD患者(男性:3/8;年龄:65.38岁[±8.73];病程:10.50年[±5.88];H&Y:2.81[±1.22];MDS-UPDRS-III:36.38[±25.34];MoCA:24.88[±5.86])和 19 例 NM-PD 患者(男性:11/19;年龄:60.53 岁[±8.00];病程:8.68 年[±5.70];H&Y:2.39 [±.51];MDS-UPDRS-III:29.95 [±11.14];MoCA:24.21 [±6.07])。RAB32-PD和NM-PD队列的FDG-PET数据和临床变量在统计学上未发现明显差异。在大多数 RAB-32 PD 患者中,观察到顶叶代谢普遍低下,这与之前报道的 LRRK2 相关 PD 和 NM-PD 的研究结果相似:本研究首次描述了RAB32-PD患者的FDG-PET发现,强调了LRRK2-和NM-PD可能存在类似的代谢低下模式。要证实这些初步结果,还需要与匹配的可比对照组进行更多的研究。
{"title":"18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant","authors":"Francesco Cavallieri ,&nbsp;Alessandro Fraternali ,&nbsp;Annachiara Arnone ,&nbsp;Valentina Fioravanti ,&nbsp;Edoardo Monfrini ,&nbsp;Francesca Di Biasio ,&nbsp;Giulia Toschi ,&nbsp;Giulia Di Rauso ,&nbsp;Giacomo Portaro ,&nbsp;Sara Grisanti ,&nbsp;Gaetano Salomone ,&nbsp;Teresa Kleinz ,&nbsp;Paola Mandich ,&nbsp;Jefri J. Paul ,&nbsp;Christian Beetz ,&nbsp;Peter Bauer ,&nbsp;Ji Hyun Ko ,&nbsp;Matteo Bauckneht ,&nbsp;Andrea Melpignano ,&nbsp;Angelina Filice ,&nbsp;Franco Valzania","doi":"10.1016/j.parkreldis.2025.107343","DOIUrl":"10.1016/j.parkreldis.2025.107343","url":null,"abstract":"<div><h3>Objective</h3><div>The RAB32 S71R variant has been linked to autosomal dominant Parkinson's disease (RAB32-PD), sharing common biological mechanisms with the leucine-rich repeat kinase-2 (LRRK2) gene. Measurement of regional differences in glucose metabolism with 18F-fluorodeoxyglucose (FDG) PET may improve the understanding of the neural mechanisms of RAB32-related PD and non-mutated PD (NM-PD). In this brief communication, we compared FDG-PET findings of eight RAB32-PD with a cohort of NM-PD.</div></div><div><h3>Methods</h3><div>Brain FDG-PET study was performed during the ON medication condition under chronic dopaminergic treatment. All images were normalized to a standard FDG-PET template, then a semi‐quantitative analysis was performed on a commercially available fully‐automated post‐processing software (Cortex ID SUITE, GE Healthcare). Clinical assessment included the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Montreal Cognitive Assessment (MoCA). Continuous variables between groups were compared through the Mann-Whitney test while nominal/ordinal variables through the chi-squared test.</div></div><div><h3>Results</h3><div>Eight RAB32-PD patients (males:3/8; age:65.38 years [±8.73]; disease duration:10.50 years [±5.88]; H&amp;Y:2.81[±1.22]; MDS-UPDRS-III:36.38 [±25.34]; MoCA:24.88[±5.86]) and 19 NM-PD patients (males:11/19; age:60.53 years [±8.00]; disease duration:8.68 years [±5.70]; H&amp;Y:2.39 [±.51]; MDS-UPDRS-III:29.95 [±11.14]; MoCA:24.21 [±6.07]) were included. No statistically significant differences in FDG-PET data and clinical variables were found between RAB32-PD and NM-PD cohorts. In the majority of RAB-32 PD patients a prevalent parietal hypometabolism was observed, similar to previous findings reported in LRRK2-related PD and NM-PD.</div></div><div><h3>Interpretation</h3><div>This study represents the first description of FDG-PET findings in RAB32-PD patients, highlighting a possible similar pattern of hypometabolism with LRRK2- and NM-PD. Additional studies with matched and comparable control cohorts are needed to confirm these preliminary results.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107343"},"PeriodicalIF":3.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response -- letter to the editor: Unraveling the neural signatures: Distinct pallidal patterns in dystonia subtypes.
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-27 DOI: 10.1016/j.parkreldis.2025.107350
Aasef G Shaikh, H A Jinnah, Alexey Sedov

We recognize the need for longitudinal measures and mechanistic understanding of the basis for phenotype to single-neuron correlations. We clarify that pallidal neuron differs across dystonia subtypes. We highlight animal studies showing how cerebellar activity can influence pallidal neuron behavior, supporting the idea of cerebellar activity transmission to the pallidum.

{"title":"Response -- letter to the editor: Unraveling the neural signatures: Distinct pallidal patterns in dystonia subtypes.","authors":"Aasef G Shaikh, H A Jinnah, Alexey Sedov","doi":"10.1016/j.parkreldis.2025.107350","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107350","url":null,"abstract":"<p><p>We recognize the need for longitudinal measures and mechanistic understanding of the basis for phenotype to single-neuron correlations. We clarify that pallidal neuron differs across dystonia subtypes. We highlight animal studies showing how cerebellar activity can influence pallidal neuron behavior, supporting the idea of cerebellar activity transmission to the pallidum.</p>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":" ","pages":"107350"},"PeriodicalIF":3.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breath hydrogen levels in patients with Parkinson's disease: A pilot cross-sectional study
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-27 DOI: 10.1016/j.parkreldis.2025.107353
Sonja Baltic , Nikola Todorovic , Sanela Popovic , Vladimir Galic , Marija Semnic , Sergej M. Ostojic
{"title":"Breath hydrogen levels in patients with Parkinson's disease: A pilot cross-sectional study","authors":"Sonja Baltic ,&nbsp;Nikola Todorovic ,&nbsp;Sanela Popovic ,&nbsp;Vladimir Galic ,&nbsp;Marija Semnic ,&nbsp;Sergej M. Ostojic","doi":"10.1016/j.parkreldis.2025.107353","DOIUrl":"10.1016/j.parkreldis.2025.107353","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107353"},"PeriodicalIF":3.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex differences in the diagnosis latency of Parkinson's disease in Latin America
IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-02-25 DOI: 10.1016/j.parkreldis.2025.107344
Janvi Ramchandra , Miguel Inca-Martinez , Thiago Peixoto Leal , Henry Mauricio Chaparro-Solano , Amira Salim , Emilia M. Gatto , Natalia González Rojas , Gustavo Da Prat , Federico Micheli , Bruno Lopes Santos-Lobato , Francisco E.C. Cardoso , Sarah Camargos , Grace H. Letro , Pedro Braga-Neto , Vitória Maria Torres Peixoto , Artur F.S. Schuh , Vitor Tumas , Manuelina M. Brito , Vanderci Borges , Carolina Candeias da Silva , Ignacio F. Mata

Background

Age and sex are known risk factors for Parkinson's Disease (PD), but it remains controversial if there are sex differences in the diagnosis latency. The objective of this study was to examine these sex differences in Latin America.

Methods

The Latin American Research Consortium on the Genetics of PD (LARGE-PD) includes PD patients from countries across Latin America who were diagnosed using the UK Brain Bank criteria. Ages at onset (AAO; N = 2,792), diagnosis (AAD; N = 1,416), and calculated diagnosis latency (N = 1,416) were extracted from the LARGE-PD database and compared for both males and females overall, by country, and decade-long age ranges. A cohort was created based on available data for motor sign at onset (N = 492). Regressions examining diagnosis latency as a factor of sex, country, and motor subtype were performed. Two-tailed t-tests at 95 % confidence intervals were used to identify differences in mean AAOs, AADs, and diagnosis latencies between the sexes.

Results

Across the LARGE-PD cohort, lower AAD was observed in males. Per country, AAO was lower for males in Mexico and diagnosis latency was shorter for males in Chile. Overall, younger females (≤39) and older males (≥70) are likely to experience longer latencies.

Conclusions

Our results suggest that there may be country and age dependent sex differences in AAO, AAD, and diagnosis latency of PD in Latin America. Interestingly, the mean AAO of LARGE-PD is approximately 6 years younger than studies done with European populations. Analyses with additional data are needed to determine the influence of other factors.
{"title":"Sex differences in the diagnosis latency of Parkinson's disease in Latin America","authors":"Janvi Ramchandra ,&nbsp;Miguel Inca-Martinez ,&nbsp;Thiago Peixoto Leal ,&nbsp;Henry Mauricio Chaparro-Solano ,&nbsp;Amira Salim ,&nbsp;Emilia M. Gatto ,&nbsp;Natalia González Rojas ,&nbsp;Gustavo Da Prat ,&nbsp;Federico Micheli ,&nbsp;Bruno Lopes Santos-Lobato ,&nbsp;Francisco E.C. Cardoso ,&nbsp;Sarah Camargos ,&nbsp;Grace H. Letro ,&nbsp;Pedro Braga-Neto ,&nbsp;Vitória Maria Torres Peixoto ,&nbsp;Artur F.S. Schuh ,&nbsp;Vitor Tumas ,&nbsp;Manuelina M. Brito ,&nbsp;Vanderci Borges ,&nbsp;Carolina Candeias da Silva ,&nbsp;Ignacio F. Mata","doi":"10.1016/j.parkreldis.2025.107344","DOIUrl":"10.1016/j.parkreldis.2025.107344","url":null,"abstract":"<div><h3>Background</h3><div>Age and sex are known risk factors for Parkinson's Disease (PD), but it remains controversial if there are sex differences in the diagnosis latency. The objective of this study was to examine these sex differences in Latin America.</div></div><div><h3>Methods</h3><div>The Latin American Research Consortium on the Genetics of PD (LARGE-PD) includes PD patients from countries across Latin America who were diagnosed using the UK Brain Bank criteria. Ages at onset (AAO; N = 2,792), diagnosis (AAD; N = 1,416), and calculated diagnosis latency (N = 1,416) were extracted from the LARGE-PD database and compared for both males and females overall, by country, and decade-long age ranges. A cohort was created based on available data for motor sign at onset (N = 492). Regressions examining diagnosis latency as a factor of sex, country, and motor subtype were performed. Two-tailed t-tests at 95 % confidence intervals were used to identify differences in mean AAOs, AADs, and diagnosis latencies between the sexes.</div></div><div><h3>Results</h3><div>Across the LARGE-PD cohort, lower AAD was observed in males. Per country, AAO was lower for males in Mexico and diagnosis latency was shorter for males in Chile. Overall, younger females (≤39) and older males (≥70) are likely to experience longer latencies.</div></div><div><h3>Conclusions</h3><div>Our results suggest that there may be country and age dependent sex differences in AAO, AAD, and diagnosis latency of PD in Latin America. Interestingly, the mean AAO of LARGE-PD is approximately 6 years younger than studies done with European populations. Analyses with additional data are needed to determine the influence of other factors.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"134 ","pages":"Article 107344"},"PeriodicalIF":3.1,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Parkinsonism & related disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1